miR‐125a‐3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor–positive breast cancer-Reference-Cited by-同舟云学术

miR‐125a‐3p inhibits ERα transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor–positive breast cancer

Published:2018-01-04 Issue:2 Volume:32 Page:588-600
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Zheng Lufeng¹²³,Meng Xia¹²,Li Xiaoman⁴,Zhang Yan¹²,Li Cheng¹²,Xiang Chenxi¹²,Xing Yingying¹²,Xia Yufeng³,Xi Tao¹²

Affiliation:

1. School of Life Science and TechnologyChina Pharmaceutical UniversityNanjingChina

2. Jiangsu Key Laboratory of Carcinogenesis and InterventionChina Pharmaceutical UniversityNanjingChina

3. Department of Pharmacology of Chinese Materia MedicaJiangsu Key Laboratory of Drug Discovery for Metabolic DiseasesChina Pharmaceutical UniversityNanjingChina

4. Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia MedicaSchool of PharmacyNanjing University of Chinese MedicineNanjingChina

Funder

Priority Academic Program Development of Jiangsu Higher Education Institutions

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.201700461RR

Reference48 articles.

1. Cancer statistics, 2014